Literature Collection

7481

Opiate use disorders and overdose: Medical students' experiences, satisfaction with learning, and attitudes toward community naloxone provision

Type: Journal Article

Authors: H. Tobin, J. Klimas, T. Barry, M. Egan, G. Bury

Year: 2018

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7482

Opioid Abuse in the U.S. and HHS Actions to Address Opioid-Drug Related Overdoses and Deaths

Type: Government Report

Authors: Office of the Assistant Secretary for Planning and Evaluation

Year: 2015

Topic(s):

, ,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

PDF (147.58 KB)

Reference Links: PDF (147.58 KB)

Export Citation: RIS

View details

7483

Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options

Type: Journal Article

Authors: J. Bonhomme, R. S. Shim, R. Gooden, D. Tyus, G. Rust

Year: 2012

Publication Place: United States

Abstract: Opioid abuse and addiction have increased in frequency in the United States over the past 20 years. In 2009, an estimated 5.3 million persons used opioid medications nonmedically within the past month, 200000 used heroin, and approximately 9.6% of African Americans used an illicit drug. Racial and ethnic minorities experience disparities in availability and access to mental health care, including substance use disorders. Primary care practitioners are often called upon to differentiate between appropriate, medically indicated opioid use in pain management vs inappropriate abuse or addiction. Racial and ethnic minority populations tend to favor primary care treatment settings over specialty mental health settings. Recent therapeutic advances allow patients requiring specialized treatment for opioid abuse and addiction to be managed in primary care settings. The Drug Addiction Treatment Act of 2000 enables qualified physicians with readily available short-term training to treat opioid-dependent patients with buprenorphine in an office-based setting, potentially making primary care physicians active partners in the diagnosis and treatment of opioid use disorders. Methadone and buprenorphine are effective opioid replacement agents for maintenance and/or detoxification of opioid-addicted individuals. However, restrictive federal regulations and stigmatization of opioid addiction and treatment have limited the availability of methadone. The opioid partial agonist-antagonist buprenorphine/naloxone combination has proven an effective alternative. This article reviews the literature on differences between buprenorphine and methadone regarding availability, efficacy, safety, side-effects, and dosing, identifying resources for enhancing the effectiveness of medication-assisted recovery through coordination with behavioral/psychological counseling, embedded in the context of recovery-oriented systems of care.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7484

Opioid Addiction in Pregnancy: Does Depression Negatively Impact Adherence With Prenatal Care?

Type: Journal Article

Authors: L. Hensley, S. Sulo, S. Kozmic, B. V. Parilla

Year: 2018

Publication Place: United States

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7485

Opioid addiction screening tools for patients with chronic noncancer pain

Type: Journal Article

Authors: A. M. dela Cruz, M. H. Trivedi

Year: 2015

Publication Place: United States

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7486

Opioid Addiction Treatment

Type: Web Resource

Authors: The University of New Mexico

Year: 2021

Publication Place: Project ECHO, The University of New Mexico

Topic(s):

, ,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

Access Resource

Reference Links: Access Resource

Export Citation: RIS

View details

7487

Opioid Addiction Treatment: A Guide for Patients, Families, and Friends

Type: Report

Authors: American Society of Addiction Medicine

Year: 2016

Topic(s):

,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

Access Resource

Reference Links: Access Resource

Export Citation: RIS

View details

7488

Opioid Addiction With Psychiatric Comorbidities

Type: Web Resource

Authors: Providers Clinical Support System

Year: 2021

Topic(s):

,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

Access Resource

Reference Links: Access Resource

Export Citation: RIS

View details

7489

Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption

Type: Journal Article

Authors: M. C. Beneitez, M. E. Gil-Alegre

Year: 2017

Publication Place: United States

Abstract: BACKGROUND: Detoxification programmes seek to implement the most secure and compassionate ways of withdrawing from opiates so that the inevitable withdrawal symptoms and other complications are minimized. Once detoxification has been achieved, the next stage is to enable the patient to overcome his or her drug addiction by ensuring consumption is permanently and completely abandoned, only after which can the subject be regarded as fully recovered. METHODS: A systematic search on the common databases of relevant papers published until 2016 inclusive. RESULTS AND CONCLUSION: Our study of the available oral treatments for opioid dependence has revealed that no current treatment can actually claim to be fully effective. These treatments require daily oral administration and, consequently, regular visits to dispensaries, which in most cases results in a lack of patient compliance, which causes fluctuations in drug plasma levels. We then reviewed alternative treatments in the available scientific literature on polymeric sustained release formulations. Research has been done not only on release systems for detoxification but also on release systems for giving up the habit of taking opioids. These efforts have obtained the recent authorization of polymeric systems for use in patients that could help them to reduce their craving for drugs.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7490

Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption

Type: Journal Article

Authors: M. C. Beneitez, M. E. Gil-Alegre

Year: 2017

Publication Place: United States

Abstract: BACKGROUND: Detoxification programmes seek to implement the most secure and compassionate ways of withdrawing from opiates so that the inevitable withdrawal symptoms and other complications are minimized. Once detoxification has been achieved, the next stage is to enable the patient to overcome his or her drug addiction by ensuring consumption is permanently and completely abandoned, only after which can the subject be regarded as fully recovered. METHODS: A systematic search on the common databases of relevant papers published until 2016 inclusive. RESULTS AND CONCLUSION: Our study of the available oral treatments for opioid dependence has revealed that no current treatment can actually claim to be fully effective. These treatments require daily oral administration and, consequently, regular visits to dispensaries, which in most cases results in a lack of patient compliance, which causes fluctuations in drug plasma levels. We then reviewed alternative treatments in the available scientific literature on polymeric sustained release formulations. Research has been done not only on release systems for detoxification but also on release systems for giving up the habit of taking opioids. These efforts have obtained the recent authorization of polymeric systems for use in patients that could help them to reduce their craving for drugs.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7491

Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series

Type: Journal Article

Authors: S. Nielsen, R. Bruno, L. Degenhardt, A. Demirkol, N. Lintzeris

Year: 2016

Topic(s):

Reference Links:

Export Citation: RIS

View details

7492

Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime

Type: Journal Article

Authors: J. Gryczynski, T. W. Kinlock, S. M. Kelly, K. E. O'Grady, M. S. Gordon, R. P. Schwartz

Year: 2012

Publication Place: United States

Abstract: This study examined outcomes and their predictors among 181 probationers enrolling in opioid agonist maintenance with methadone or levo-alpha-acetylmethadol (LAAM). Participants were interviewed at treatment entry and 2-, 6-, and 12-month follow-ups. Treatment retention and frequency of heroin use, cocaine use, and income-generating criminal activity were examined using survival and longitudinal analyses. Participants reported marked reductions in drug use and crime relative to treatment entry. A number of patient characteristics associated with various outcomes were identified. The findings support engaging probationers in treatment and highlight patient factors that might influence outcomes.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7493

Opioid agonist therapy and mortality among First Nations and other residents with concurrent alcohol use disorder in British Columbia, Canada: A population-based cohort study

Type: Journal Article

Authors: B. Barker, J. E. Min, F. Homayra, M. Piske, S. Sabeti, L. Meilleur, B. Nosyk, N. Wieman

Year: 2023

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7494

Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder

Type: Government Report

Authors: Centre for Addiction and Mental Health

Year: 2021

Abstract:

"Canada is in the midst of an opioid crisis, making it important to disseminate standardized approaches and evidence-based recommendations for managing opioid use disorder. Opioid Agonist Treatment: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder is a national clinical guideline that harmonizes existing provincial and national guidelines, evidence-based practices and expert opinions into one document aimed at providing consistent and high-quality care to people with opioid use disorder. Opioid agonist therapy is the most effective treatment option for opioid use disorder, ideally combined with behavioural and social supports. It can stabilize the cycle of intoxication and withdrawal, reduce opioid cravings and block the intoxicating effects of other short-acting opioids, including fentanyl. People who are maintained on opioid agonist therapy typically experience improved health and social functioning and reduced risk of overdose. CAMH worked with subject matter experts and medical regulatory authorities across Canada to reach consensus on recommendations from existing guidelines. The aim of this unified guideline is to standardize expectations for Canadian prescribers, but not to replace any adopted guidelines. Please consult your professional regulatory body for specific guidance in your jurisdiction."--

Topic(s):

, ,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

Access Resource

Reference Links: Access Resource

Export Citation: RIS

View details

7495

Opioid agonist treatment and the process of injection drug use initiation

Type: Journal Article

Authors: M. L. Mittal, S. Jain, S. Sun, K. DeBeck, M. J. Milloy, K. Hayashi, S. E. Hadland, D. Werb

Year: 2019

Publication Place: Ireland

Topic(s):

Reference Links:

Export Citation: RIS

View details

7496

Opioid agonist treatment for pharmaceutical opioid dependent people

Type: Journal Article

Authors: S. Nielsen, B. Larance, L. Degenhardt, L. Gowing, C. Kehler, N. Lintzeris

Year: 2016

Publication Place: England

Abstract: BACKGROUND: There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment research has been conducted in people who use heroin. OBJECTIVES: To assess the effects of maintenance agonist pharmacotherapy for the treatment of pharmaceutical opioid dependence. SEARCH METHODS: The search included the Cochrane Drugs and Alcohol Group's Specialised Register of Trials; the Cochrane Central Register of Controlled Trials (CENTRAL, 2015, Issue 5); PubMed (January 1966 to May 2015); EMBASE (Ovid) (January 1974 to May 2015); CINAHL (EBSCOhost) (1982 to May 2015); ISI Web of Science (to May 2014); and PsycINFO (Ovid) (1806 to May 2014). SELECTION CRITERIA: We included randomised controlled trials examining maintenance opioid agonist treatments that made the following two comparisons:1. full opioid agonists (methadone, morphine, oxycodone, levo-alpha-acetylmethadol (LAAM), or codeine) versus different full opioid agonists or partial opioid agonists (buprenorphine) for maintenance treatment and2. full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment (without opioid agonist treatment). DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. MAIN RESULTS: We identified six randomised controlled trials that met inclusion criteria (607 participants).We found moderate quality evidence from two studies of no difference between methadone and buprenorphine in self reported opioid use (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.08 to 1.63) or opioid positive urine drug tests (RR 0.81, 95% CI 0.56 to 1.18). There was low quality evidence from three studies of no difference in retention between buprenorphine and methadone maintenance treatment (RR 0.69, 95% CI 0.39 to 1.22). There was moderate quality evidence from two studies of no difference between methadone and buprenorphine on adverse events (RR 1.10, 95% CI 0.64 to 1.91).We found low quality evidence from three studies favouring maintenance buprenorphine treatment over detoxification or psychological treatment in terms of fewer opioid positive urine drug tests (RR 0.63, 95% CI 0.43 to 0.91) and self reported opioid use in the past 30 days (RR 0.54, 95% CI 0.31 to 0.93). There was no difference on days of unsanctioned opioid use (standardised mean difference (SMD) -0.31, 95% CI -0.66 to 0.04). There was moderate quality evidence favouring buprenorphine maintenance over detoxification or psychological treatment on retention in treatment (RR 0.33, 95% CI 0.23 to 0.47). There was moderate quality evidence favouring buprenorphine maintenance over detoxification or psychological treatment on adverse events (RR 0.19, 95% CI 0.06 to 0.57).The main weaknesses in the quality of the data was the use of open-label study designs. AUTHORS' CONCLUSIONS: There was low to moderate quality evidence supporting the use of maintenance agonist pharmacotherapy for pharmaceutical opioid dependence. Methadone or buprenorphine appeared equally effective. Maintenance treatment with buprenorphine appeared more effective than detoxification or psychological treatments.Due to the overall low to moderate quality of the evidence and small sample sizes, there is the possibility that the further research may change these findings.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7497

Opioid agonist treatment recipients within criminal justice-involved populations

Type: Journal Article

Authors: Wendy P. Guastaferro, Deborah Koetzle, Laura Lutgen-Nieves, Brent Teasdale

Year: 2022

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7498

Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada

Type: Journal Article

Authors: Megan Kurz, Laura M. Dale, Jeong Eun Min, Natt Hongdilokkul, Leigh Greiner, Maureen Olley, Katherine E. McLeod, Amanda Slaunwhite, Bohdan Nosyk

Year: 2022

Topic(s):

, ,

Reference Links:

Export Citation: RIS

View details

7499

Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada

Type: Journal Article

Authors: Megan Kurz, Laura M. Dale, Jeong Eun Min, Natt Hongdilokkul, Leigh Greiner, Maureen Olley, Katherine E. McLeod, Amanda Slaunwhite, Bohdan Nosyk

Year: 2021

Topic(s):

, ,

Reference Links:

Export Citation: RIS

View details

7500

Opioid Analgesic Drugs Measure: Nurses' knowledge of opioid analgesic drugs and psychological dependence

Type: Journal Article

Authors: M. McCaffery, B. Ferrell, E. O'Neil-Page, M. Lester, B. Ferrell

Year: 1990

Topic(s):

,

Export Citation: RIS

View details